Jun 3, 2022
The company reported $1.52 in earnings per share, growing from $0.41 last year.
The stock is highly attractive at $7.55 with great potential for multiplying investor value.
Immatics N.V. (NASDAQ:IMTX) is currently valued at $7.55. The stock has been bullish over the last three weeks. In that period, it emerged from the bottom at $6.60 and the lowest price of $5.75. Our analysis shows that the stock carries a lot of potential for patient investors.
Immatics is little known to many investors. The company focuses particularly on cancer immunotherapies. The company just released earnings showing an EPS of $1.52. This is lower than the consensus estimate of $1.86, but that is not a major concern. The greater challenge is that the earnings are very erratic. That is characteristic of a biotechnology stock whose products are yet to establish a market.
Are you looking for fast-news, hot-tips and market analysis?
Sign-up for the Invezz newsletter, today.
Our analysis shows that Immatics is a highly promising stock. The main beneficiaries will be those investors who buy the stock early. The valuation means the stock is likely to be highly volatile. It also means that slight price movements are likely to generate very high returns for investors.
Immatics has been gaining silently over the last three weeks
Source – TradingView
Our analysis indicates that Immatics has been silently bullish over the last three weeks. This trend is projected to continue in the coming days. While the stock faces resistance at $9.50, this analysis sets a target above $12 in the coming few weeks. The RSI points upwards, indicating that the stock is building bullish momentum.
This analysis strongly recommends buying and accumulating Immatics. The biotechnology company holds highly promising immunotherapies for cancer patients. While the performance appears volatile, it will stabilize and expand as the market grows.
Where to buy right now
To invest simply and easily, users need a low-fee broker with a track record of reliability. The following brokers are highly rated, recognised worldwide, and safe to use:
*Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.
Stocks & Shares